Bariatric surgery and prevention of cardiovascular events and mortality in morbid obesity: Mechanisms of action and choice of surgery

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 5, 2015, Pages 437-443

  Boido, A ^a   Ceriani, V ^b   Cetta, F ^b   Lombardi, F ^a,c   Pontiroli, A E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Bariatric surgery; Cardiovascular disease; Gastric banding; Gastric bypass; Morbid obesity; Obesity; Sleeve gastrectomy

Indexed keywords

APOLIPOPROTEIN A;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; FATTY LIVER; GASTRIC BANDING; HEART INFARCTION; HUMAN; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORBID OBESITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; GASTRECTOMY; GASTROPLASTY; OBESITY, MORBID; PERSONALIZED MEDICINE;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; COMORBIDITY; EVIDENCE-BASED MEDICINE; GASTRECTOMY; GASTRIC BYPASS; GASTROPLASTY; HUMANS; OBESITY, MORBID; PRECISION MEDICINE; WEIGHT LOSS;

EID: 84927800486     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.01.011     Document Type: Review

References (90)

1. Alvarez-Cordero R. Treatment of clinically severe obesity - a public health problem: introduction. World J Surg 1998, 22:905-906.
2. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003, 163:2146-2148.
3. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterol Clin North Am 2010, 39:1-7.
4. Van Itallie T.B. Obesity: adverse effects on health and longevity. Am J Clin Nutr 1979, 32:2723-2733.
5. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006, 355:763-778.
6. Berrington de Gonzalez A., Hartge P., Cerhan J.R., Flint A.J., Hannan L., MacInnis R.J., et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010, 363:2211-2219.
7. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096.
8. Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Al Mamun A., Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003, 138:24-32. NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group.
9. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
10. Davos C.H., Doehner W., Rauchhaus M., Cicoira M., Francis D.P., Coats A.J., et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003, 9:29-35.
11. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009, 26:1925-1932.
12. Das S.R., Alexander K.P., Chen A.Y., Powell-Wiley T.M., Diercks D.B., Peterson E.D., et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (national cardiovascular data registry). J Am Coll Cardiol 2011, 5(8):2642-2650.
13. Niedziela J., Hudzik B., Niedziela N., Gasior M., Gierlotka M., Wasilewski J., et al. The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol 2014, 29:801-812.
14. Dixon J.B., Lambert G.W. The obesity paradox: a reality that requires explanation and clinical interpretation. Atherosclerosis 2013, 226:47-48.
15. Lavie C.J., De Schutter A., Patel D.A., Milani R.V. Body composition and fitness in the obesity paradox. Body mass index alone does not tell the whole story. Prev Med 2013, 57:1-2.
16. Banack H.R., Kaufman J.S. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 2014, 10(62):96-102.
17. Bastien M., Poirier P., Lemieux I., Després J.P. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014, 56:369-381.
18. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
19. Sjöström L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patient. Lancet 1998, 352:167-172. European Multicenter Orlistat Study Group.
20. Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
21. Després J.P., Golay A., Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134. Rimonabant in Obesity-Lipids Study Group.
22. Williamson D.F., Thompson T.J., Thun M., Flanders D., Pamuk E., Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
23. The Look Ahead Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.
24. Li G., Zhang P., Wang J., Gregg E.W., Yang W., Gong Q., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
25. Uusitupa M., Peltonen M., Lindström J., Aunola S., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., et al. Ten-year mortality and cardiovascular morbidity in the Finnish diabetes prevention study-secondary analysis of the randomized trial. PLoS One 2009, 4:e5656. Finnish Diabetes Prevention Study Group.
26. Nissen S.E., Nicholls S.J., Wolski K., Rodés-Cabau J., Cannon C.P., Deanfield J.E., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J Am Med Assoc 2008, 299:1547-1560. STRADIVARIUS Investigators.
27. James W.P., Caterson I.D., Coutinho W., Finer N., Van Gaal L.F., Maggioni A.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363:905-917. SCOUT Investigators.
28. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., et al. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 2004, 292:1724-1737.
29. Arterburn D.E., Courcoulas A.P. Bariatric surgery for obesity and metabolic conditions in adults. BMJ 2014, 349:g3961.
30. Sjöström L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693. Swedish Obese Subjects Study Scientific Group.
31. Dixon J.B., O'Brien P.E., Playfair J., Chapman L., Schachter L.M., Skinner S., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. J Am Med Assoc 2008, 299:316-323.
32. Schauer P.R., Kashyap S.R., Wolski K., Brethauer S.A., Kirwan J.P., Pothier C.E., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.
33. Mingrone G., Panunzi S., De Gaetano A., Guidone C., Iaconelli A., Leccesi L., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366:1577-1585.
34. Buchwald H., Estok R., Fahrbach K., Banel D., Jensen M.D., Pories W.J., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.
35. Vest A.R., Heneghan H.M., Agarwal S., Schauer P.R., Young J.B. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012, 98:1763-1777.
36. Gloy V.L., Briel M., Bhatt D.L., Kashyap S.R., Schauer P.R., Mingrone G., et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. Br Med J 2013, 347:f5934.
37. Ribaric G., Buchwald J.N., McGlennon T.W. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg 2014, 24:437-455.
38. Pontiroli A.E., Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011, 253:484-487.
39. Sjöström L., Peltonen M., Jacobson P., Sjöström C.D., Karason K., Wedel H., et al. Bariatric surgery and long term cardiovascular events. J Am Med Assoc 2012, 307:56-65.
40. Johnson R.J., Johnson B.L., Blackhurst D.W., Bour E.S., Cobb W.S., Carbonell A.M., et al. Bariatric surgery is associated with a reduced risk of mortality in morbidly obese patients with a history of major cardiovascular events. Am Surg 2012, 78:685-692.
41. Plecka Östlund M., Marsk R., Rasmussen F., Lagergren J., Näslund E. Morbidity and mortality before and after bariatric surgery for morbid obesity compared with the general population. Br J Surg 2011, 98:811-816.
42. Kwok C.S., Pradhan A., Khan M.A., Anderson S.G., Keavney B.D., Myint P.K., et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 2014, 173:20-28.
43. Society of American Gastrointestinal and Endoscopic Surgeons SAGES guideline for clinical application of laparoscopic bariatric surgery. Surg Obes Relat Dis 2009, 5:387-405.
44. Largent J.A., Vasey J., Bessonova L., Okerson T., Wong N.D. Reduction in Framingham risk of cardiovascular disease in obese patients undergoing laparoscopic adjustable gastric banding. Adv Ther 2013, 30:684-696.
45. Busetto L., De Stefano F., Pigozzo S., Segato G., De Luca M., Favretti F. Long-term cardiovascular risk and coronary events in morbidly obese patients treated with laparoscopic gastric banding. Surg Obes Relat Dis 2014, 10:112-120.
46. Aminian A., Daigle C.R., Romero-Talamás H., Kashyap S.R., Kirwan J.P., Brethauer S.A., et al. Risk prediction of complications of metabolic syndrome before and 6 years after gastric bypass. Surg Obes Relat Dis 2014, 10:576-582.
47. Uzun H., Zengin K., Taskin M., Aydin S., Simsek G., Dariyerli N. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004, 14:659-665.
48. Pontiroli A.E., Pizzocri P., Koprivec D., Vedani P., Marchi M., Arcelloni C., et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 2004, 150:195-200.
49. García de la Torre N., Rubio M.A., Bordiú E., Cabrerizo L., Aparicio E., Hernández C., et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008, 93:4276-4281.
50. Perego L., Pizzocri P., Corradi D., Maisano F., Paganelli M., Fiorina P., et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 2005, 90:4087-4093.
51. Veronelli A., Laneri M., Ranieri R., Koprivec D., Vardaro D., Paganelli M., et al. White blood cells in obesity and diabetes: effects of weight loss and normalization of glucose metabolism. Diabetes Care 2004, 27:2501-2502.
52. Frige' F., Laneri M., Veronelli A., Folli F., Paganelli M., Vedani P., et al. Bariatric surgery in obesity: changes of glucose and lipid metabolism correlate with changes of fat mass. Nutr Metab Cardiovasc Dis 2009, 19:198-204.
53. Bacci V., Basso M.S., Greco F., Lamberti R., Elmore U., Restuccia A., et al. Modifications of metabolic and cardiovascular risk factors after weight loss induced by laparoscopic gastric banding. Obes Surg 2002, 12:77-82.
54. Urbanavičius V., Abalikšta T., Brimas G., Abraitiene A., Gogeliene L., Strupas K. Comparison of changes in blood glucose, insulin resistance indices, and adipokine levels in diabetic and nondiabetic subjects with morbid obesity after laparoscopic adjustable gastric banding. Med (Kaunas) 2013, 49:9-14.
55. Sturm W., Tschoner A., Engl J., Kaser S., Laimer M., Ciardi C., et al. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis. Eur Heart J 2009, 30:2038-2043.
56. Raffaelli M., Guidone C., Callari C., Iaconelli A., Bellantone R., Mingrone G. Effect of gastric bypass versus diet on cardiovascular risk factors. Ann Surg 2014, 259:694-699.
57. Pontiroli A.E., Merlotti C., Veronelli A., Lombardi F. Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet. Acta Diabetol 2013, 50:843-850.
58. Pontiroli A.E., Pizzocri P., Saibene A., Girola A., Koprivec D., Fragasso G. Left ventricular hypertrophy and QT interval in obesity and in hypertension: effects of weight loss and of normalisation of blood pressure. Int J Obes Relat Metab Disord 2004, 28:1118-1123.
59. Cuspidi C., Sala C., Rescaldani M., Tadic M., Grassi G. Effects of bariatric surgery on right ventricular structure and function. J Cardiovasc Med (Hagerstown) 2014, 15:731-737.
60. O'Brien P.E., Sawyer S.M., Laurie C., Brown W.A., Skinner S., Veit F., et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. J Am Med Assoc 2010, 303:519-526.
61. O'Brien P.E., Dixon J.B., Laurie C., Skinner S., Proietto J., McNeil J., et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006, 144:625-633.
62. Calori G., Lattuada G., Ragogna F., Garancini M.P., Crosignani P., Villa M., et al. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology 2011, 54:145-152.
63. Folini L., Veronelli A., Benetti A., Pozzato C., Cappelletti M., Masci E., et al. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon and gastric banding. Acta Diabetol 2014, 51:361-368.
64. Dixon J.B., Bhathal P.S., O'Brien P.E. Weight loss and non-alcoholic fatty liver disease: falls in gamma glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006, 16:1278-1286.
65. Agrawal V., Krause K.R., Chengelis D.L., Zalesin K.C., Rocher L.L., McCullough P.A. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis 2009, 5:20-26.
66. Iaconelli A., Panunzi S., De Gaetano A., Manco M., Guidone C., Leccesi L., et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care 2011, 34:561-567.
67. Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013, 23:427-436.
68. Garb J., Welch G., Zagarins S., Kuhn J., Romanelli J. Bariatric surgery for the treatment of morbid obesity: a meta-analysis of weight loss outcomes for laparoscopic adjustable gastric banding and laparoscopic gastric bypass. Obes Surg 2009, 19:1447-1455.
69. O'Brien P.E., McPhail T., Chaston T.B., Dixon J.B. Systematic review of medium-term weight loss after bariatric operations. Obes Surg 2006, 16:1032-1040.
70. Padwal R., Klarenbach S., Wiebe N., Birch D., Karmali S., Manns B., et al. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes Rev 2011, 12:602-621.
71. Chang S.H., Stoll C.R., Song J., Varela J.E., Eagon C.J., Colditz G.A. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014, 149:275-287.
72. Carlin A.M., Zeni T.M., English W.J., Hawasli A.A., Genaw J.A., Krause K.R., et al. The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. Ann Surg 2013, 257:791-797. Michigan Bariatric Surgery Collaborative.
73. Chakravarty P.D., McLaughlin E., Whittaker D., Byrne E., Cowan E., Xu K., et al. Comparison of laparoscopic adjustable gastric banding (LAGB) with other bariatric procedures; a systematic review of the randomised controlled trials. Surgeon 2012, 10:172-182.
74. Nguyen N.T., Slone J.A., Nguyen X.M., Hartman J.S., Hoyt D.B. A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg 2009, 250:631-641.
75. Angrisani L., Lorenzo M., Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis 2007, 3:127-132.
76. Spivak H., Abdelmelek M.F., Beltran O.R., Ng A.W., Kitahama S. Long-term outcomes of laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass in the United States. Surg Endosc 2012, 26:1909-1919.
77. Tolonen P., Victorzon M., Mäkelä J. 11-year experience with laparoscopic adjustable gastric banding for morbid obesity-what happened to the first 123 patients?. Obes Surg 2008, 18:251-255.
78. Suter M., Calmes J.M., Paroz A., Giusti V.A. 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. Obes Surg 2006, 16:829-835.
79. Himpens J., Cadière G.B., Bazi M., Vouche M., Cadière B., Dapri G. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011, 146:802-807.
80. Benetti A., Del Puppo M., Crosignani A., Veronelli A., Masci E., Frigè F., et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures. Diabetes Care 2013, 36:1443-1447.
81. Pontiroli A.E., Laneri M., Veronelli A., Frigè F., Micheletto G., Folli F., et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol 2009, 8:37.
82. Vila M., Ruíz O., Belmonte M., Riesco M., Barceló A., Perez G., et al. Changes in lipid profile and insulin resistance in obese patients after scopinaro biliopancreatic diversion. Obes Surg 2009, 19:299-306.
83. Lubrano C., Mariani S., Badiali M., Cuzzolaro M., Barbaro G., Migliaccio S., et al. Metabolic or bariatric surgery? long-term effects of malabsorptive vs restrictive bariatric techniques on body composition and cardiometabolic risk factors. Int J Obes (Lond) 2010, 34:1404-1414.
84. Wang S., Li P., Sun X.F., Ye N.Y., Xu Z.K., Wang D. Comparison between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding for morbid obesity: a meta-analysis. Obes Surg 2013, 23:980-986.
85. Langer F.B., RezaHoda M.A., Bohdjalian A., Felberbauer F.X., Zacherl J., Wenzl E., et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005, 15:1024-1029.
86. Woodard G.A., Peraza J., Bravo S., Toplosky L., Hernandez-Boussard T., Morton J.M. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg 2010, 20:578-582.
87. Correspondence Cardiovascular events after bariatric surgery. J Am Med Assoc 2012, 307:1577-1578.
88. Rohde U., Hedbäck N., Gluud L.L., Vilsbøll T., Knop F.K. Effect of the endo barrier gastrointestinal liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. BMJ Open 2013, 3:e003417.
89. Tagliabue A., Elli M. The role of gut microbiota in human obesity: recent findings and future perspectives. Nutr Metab Cardiovasc Dis 2013, 23:160-168.
90. Brethauer S.A., Aminian A., Romero-Talamás H., Batayyah E., Mackey J., Kennedy L., et al. Can diabetes be surgically cured? long-term metabolic effects of bariatric surgery in obese patients with type2 diabetes mellitus. Ann Surg 2013, 258:628-636.